C Aigner
Overview
Explore the profile of C Aigner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
118
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sarova P, Mosleh B, Zehetmayer S, Oberndorfer F, Widder J, Prosch H, et al.
Thorac Cancer
. 2024 Jun;
15(20):1598-1606.
PMID: 38860475
Background: Programmed cell death-ligand 1 (PD-L1) expression is a well-established biomarker for predicting responses to immune checkpoint inhibitors and certain targeted therapies. As a result, treatment strategies for patients vary...
2.
Auner S, Hillebrand C, Boehm P, Boecker J, Koren D, Schwarz S, et al.
Transpl Int
. 2024 May;
37:12774.
PMID: 38779355
Lung transplantation (LuTx) is an established treatment for patients with end-stage lung diseases, however, outcomes are limited by acute and chronic rejection. One aspect that has received increasing attention is...
3.
Aigner C, Bruning T, Eberhardt W, Harter M, Kaelberlah H, Metzenmacher M, et al.
Pneumologie
. 2021 May;
75(10):776-794.
PMID: 33946118
Asbestos-related mesotheliomas belong to the group of the most frequent occupational diseases in Germany, reaching about 1,000 new cases per year. The disease has a dismal prognosis because most tumors...
4.
Albrecht S, Taube C, Aigner C, Theegarten D
Pneumologie
. 2020 Sep;
75(6):453-456.
PMID: 32927488
The determination of exercise-induced dyspnea is an important multifaceted task for a differential diagnosis of the pulmonologist. We are reporting the case of a 70-year old female patient at the...
5.
Aigner C
Pathologe
. 2019 Nov;
40(Suppl 3):363-365.
PMID: 31712888
Background: Lung transplantation is the established treatment of benign end-stage pulmonary diseases after failure of alternative surgical and medical treatment options. The aim of this paper is to provide an...
6.
Wiesweg M, Mairinger F, Reis H, Goetz M, Walter R, Hager T, et al.
Ann Oncol
. 2019 Feb;
30(4):655-657.
PMID: 30753264
No abstract available.
7.
Bessa V, Bonella F, Ohshimo S, Weinreich G, Kleibrink B, Costabel U, et al.
Transpl Immunol
. 2018 Nov;
52:40-44.
PMID: 30391371
Chronic lung allograft dysfunction (CLAD) remains a leading cause of death after lung transplantation. KL-6 is a reliable biomarker for various interstitial lung diseases and levels are increased in lung...
8.
Ploenes T, Aigner C
Chirurg
. 2017 Dec;
89(6):440-447.
PMID: 29188355
Background: Neuroendocrine tumors of the lungs are a very inhomogeneous group of malignancies. The surgical treatment should be adapted to the anatomical localization and histological subtype and individualized according to...
9.
Shafaghi S, Najafizadeh K, Sheikhy K, Ansari Aval Z, Farzanegan B, Mafhoomi Y, et al.
Int J Organ Transplant Med
. 2017 Jan;
7(4):219-227.
PMID: 28078061
Background: Although lung transplantation is a well-accepted treatment for end-stage lung diseases patients, only 15%-20% of the brain-dead donors' lungs are usable for transplantation. This results in high mortality of...
10.
Gaggl M, Aigner C, Sunder-Plassmann G, Schmidt A
Med Klin Intensivmed Notfmed
. 2016 Jun;
111(5):434-9.
PMID: 27255224
Thrombotic microangiopathy (TMA) is a clinical syndrome that is characterized by hemolysis, thrombocytopenia, and acute kidney injury, known as atypical hemolytic syndrome (aHUS), thrombotic thrombocytopenic purpura (TTP), and shigatoxin-associated HUS...